| Print
Cassava Sciences (SAVA)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Address
7801 N. Capital of Texas Highway
Suite 260
Austin
TX
USA
78731
Telephone
+1 512 501 2444
Forecast key dates
| Name | Key Date |
|---|---|
| Cassava Sciences Inc Fourth Quarter Earnings Results for 2025 | 2026-03-03T00:00:00 |
| Cassava Sciences Inc Annual Report for 2025 | 2026-03-03T00:00:00 |
| Cassava Sciences Inc Third Quarter Earnings Conference Call for 2025 | 2025-11-07T08:30:00 |
| Cassava Sciences Inc Third Quarter Earnings Results for 2025 | 2025-11-07T00:00:00 |
| Cassava Sciences Inc Second Quarter Earnings Conference Call for 2025 | 2025-08-08T08:30:00 |
| Cassava Sciences Inc Second Quarter Earnings Results for 2025 | 2025-08-08T00:00:00 |
| Cassava Sciences Inc Annual General Meeting for 2025 | 2025-05-09T10:00:00 |
| Cassava Sciences Inc First Quarter Earnings Results for 2025 | 2025-05-09T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Cassava Sciences Inc Annual General Meeting for 2025 | 2025-05-09T10:00:00 |
| Cassava Sciences Inc First Quarter Earnings Results for 2025 | 2025-05-09T00:00:00 |
| Cassava Sciences Inc Fourth Quarter Earnings Results for 2024 | 2025-03-03T00:00:00 |
| Cassava Sciences Inc Annual Report for 2024 | 2025-03-03T00:00:00 |
| Cassava Sciences to Hold Corporate Update | 2024-11-25T08:00:00 |
| Cassava Sciences Inc Third Quarter Earnings Conference Call for 2024 | 2024-11-07T08:30:00 |
| Cassava Sciences Inc Third Quarter Earnings Result for 2024 | 2024-11-07T00:00:00 |
| H.C. Wainwright 26th Annual Global Investment Conference | 2024-09-09T15:00:00 |
| Cassava Sciences Inc Second Quarter Earnings Conference Call for 2024 | 2024-08-08T08:30:00 |
| Cassava Sciences Inc Second Quarter Earnings Result for 2024 | 2024-08-08T00:00:00 |
| Cassava Sciences Inc First Quarter Earnings Results for 2024 | 2024-05-10T00:00:00 |
| Cassava Sciences Inc Annual General Meeting for 2024 | 2024-05-09T10:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.